A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t
Introduction 51
Enterobacter cloacae is the most important nosocomial pathogen in the genus 52
Enterobacter and is of increasing concern to clinicians owing to the many isolates that 53 are multi-drug resistant. Tigecycline has good in vitro activity against E. cloacae and 54 is a welcome addition to the armamentarium (1), however, E. cloacae is the least 55 susceptible member of the genus to this compound (2) and cases of emerging 56 resistance have been described (3-5). Where their mechanisms have been investigated, 57 up-regulation of the RND efflux system AcrAB and the global regulator RamA have 58 been implicated (5). 59
60
We investigated the role of these components in an E. cloacae strain that developed 61 tigecycline resistance during ciprofloxacin treatment and in vitro, under tigecycline 62 pressure. 63 64
Case report 65
In 2006, a patient presented with a ten-day history of progressively increasing back 66 pain, high fever (40ºC) and swelling over the spine. He had had two previous 67 operations for stabilisation of a lumbar spinal fracture, 20 months, followed by a 68 revision 16 months, prior to this event. An aspirate revealed two colony variants of 69
Enterobacter cloacae which varied in their antibiotic susceptibility patterns. Both 70 appeared sensitive to ciprofloxacin and the initial regimen was changed to 71 ciprofloxacin (400mg 12 hourly iv) on day four after admission. A definitive surgical 72 procedure was performed three days later and one litre of pus and all the metalwork 73 (eight screws and plates) were removed. The same organisms were isolated again but 74 they now showed changes in antibiotic resistance patterns, with one variant now 75 M a n u s c r i p t Sensitest agar and MICs were interpreted using BSAC breakpoints (6). 98 99
Laboratory-selection of mutants 100
Clinical isolate TGC-S was passaged with serially increasing concentrations of 101 tigecycline in Iso-Sensitest broth, beginning at half the MIC (0.25 mg/L) and the 102 tigecycline concentration doubled every 24 hours until there was no further growth. 103
MICs for mutants were determined daily by E-test. PFGE profiles of the final mutant 104 (TGC-S7) and all intermediates were compared with that of isolate TGC-S in order to 105 confirm parentage. 106 107 M a n u s c r i p t
DNA manipulations and GenBank accession number 109
Gel electrophoresis and restriction enzyme digestion were performed as previously 110 described (7). Genomic DNA was isolated using the Wizard Genomic DNA 111
Purification Kit (Promega, Southampton, UK) and was used as the template for PCR. 112
Plasmids were isolated from α-select Escherichia coli (Bioline, London, UK) using 113 the PureYield Plasmid Miniprep System (Promega). PCR products were purified 114 using the Geneclean Turbo for PCR (MP Biomedicals, Strasbourg, France). DNA into SmaI/HindIII-digested pBADKM to produce plasmid pBADKM-R, which was 154 transformed into isolate TGC-S for the ramA overexpression studies; vector 155 pBADKM was used as a negative control. (Table 1 ). These data confirm that up-regulation of AcrAB, mediated by RamA 234 activation, was the factor conferring tigecycline resistance in E. cloacae. 235
236
To our knowledge, this is the first report of emergence of resistance to tigecycline 237 associated with ciprofloxacin therapy, rather than tigecycline therapy. Ciprofloxacin is 238 known to be a substrate of AcrAB in E. cloacae (9) and it is possible that exposure to 239 ciprofloxacin selected for AcrAB up-regulation, which resulted in cross-resistance to A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Edited Figure 2 
